JP2025511096A5 - - Google Patents
Info
- Publication number
- JP2025511096A5 JP2025511096A5 JP2024557799A JP2024557799A JP2025511096A5 JP 2025511096 A5 JP2025511096 A5 JP 2025511096A5 JP 2024557799 A JP2024557799 A JP 2024557799A JP 2024557799 A JP2024557799 A JP 2024557799A JP 2025511096 A5 JP2025511096 A5 JP 2025511096A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- hbsag
- human
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263324662P | 2022-03-29 | 2022-03-29 | |
| US63/324,662 | 2022-03-29 | ||
| US202263365535P | 2022-05-31 | 2022-05-31 | |
| US63/365,535 | 2022-05-31 | ||
| US202263374393P | 2022-09-02 | 2022-09-02 | |
| US63/374,393 | 2022-09-02 | ||
| PCT/IB2023/053022 WO2023187612A1 (en) | 2022-03-29 | 2023-03-27 | Method of treating chronic hepatitis b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511096A JP2025511096A (ja) | 2025-04-15 |
| JP2025511096A5 true JP2025511096A5 (https=) | 2026-04-02 |
Family
ID=86053618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557799A Pending JP2025511096A (ja) | 2022-03-29 | 2023-03-27 | 慢性ｂ型肝炎を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250215431A1 (https=) |
| EP (1) | EP4499110A1 (https=) |
| JP (1) | JP2025511096A (https=) |
| KR (1) | KR20240168390A (https=) |
| AU (1) | AU2023247291A1 (https=) |
| CA (1) | CA3246695A1 (https=) |
| WO (1) | WO2023187612A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202340468A (zh) | 2022-01-10 | 2023-10-16 | 中國大陸商杭州浩博醫藥有限公司 | B型肝炎病毒(hbv)表現之調節 |
| WO2025242321A1 (en) * | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61447B1 (sr) | 2011-04-21 | 2021-03-31 | Glaxo Group Ltd | Modulacija ekspresije virusa hepatitisa b (hbv) |
-
2023
- 2023-03-27 KR KR1020247035517A patent/KR20240168390A/ko active Pending
- 2023-03-27 JP JP2024557799A patent/JP2025511096A/ja active Pending
- 2023-03-27 WO PCT/IB2023/053022 patent/WO2023187612A1/en not_active Ceased
- 2023-03-27 EP EP23718050.0A patent/EP4499110A1/en active Pending
- 2023-03-27 CA CA3246695A patent/CA3246695A1/en active Pending
- 2023-03-27 AU AU2023247291A patent/AU2023247291A1/en active Pending
- 2023-03-27 US US18/851,303 patent/US20250215431A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025511096A5 (https=) | ||
| JP2024133475A5 (https=) | ||
| JP2022532211A5 (https=) | ||
| ES2844629T3 (es) | Tratamiento de la infección por el virus de la hepatitis delta | |
| US20230044958A1 (en) | Method of treating virus infection using a tlr7 agonist | |
| KR20170066339A (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| CN106535895A (zh) | 丁型肝炎病毒感染的治疗 | |
| JP2022545920A5 (https=) | ||
| Liu et al. | Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study | |
| JP2017536403A5 (https=) | ||
| US20180338993A1 (en) | Treatment of hepatitis delta virus infection | |
| US20220370447A1 (en) | Method of treating hbv infection using a core protein allosteric modulator | |
| ES2991384T3 (es) | Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C) | |
| JP2022518527A5 (https=) | ||
| EP3999069B1 (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| KR20120125253A (ko) | Ｂ형 간염 바이러스 감염 치료용 조성물 및 치료방법 | |
| CN108371712B (zh) | 咖啡因与PPARγ激动剂联合制备AD药物中的用途 | |
| US20220047606A1 (en) | Treatment method with iap inhibitor | |
| HK40066536B (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| HK40066536A (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| EP4029503B1 (en) | Drug combinations of entecavir and a tlr7 agonist for use in the treatment of hbv | |
| EA046230B1 (ru) | Синергическое действие eyp001 и ifn при лечении инфекции hbv | |
| Korkmaz et al. | Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients | |
| Quan | Pharmacotherapy of hepatitis B infection: a brief review. | |
| CN113827597A (zh) | 化合物在制备治疗特发性肺纤维化的药物中的应用 |